ReviewMaedica2025
Recent Advances in Forensic Medicine at the Horizon of Omics Sciences and New Biomarkers for Postmortem Interval Estimation.
Review in Maedica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: To present recent advances in forensic sciences with omics sciences and new biomarkers for postmortem interval (PMI) estimation. Materials and methods: We conducted a narrative review screening PubMed and Scopus databases in the last 10 years (2015-2025) with the following keywords in the title and abstract: "postmortem interval" OR "post-mortem interval" AND "proteomics" OR "proteomic" OR "metabolomics" OR "metabolomic" OR "transcriptomic" OR transcriptomics" OR microRNA" OR "microRNAs" OR "lipidomic". Results: Conventional methods of postmortem interval estimation are presented. Some of the most important studies and molecular techniques in genomics, transcriptomics, proteomics, metabolomics, lipidomics, old and new biomarkers for postmortem interval estimation are summarized. Single-omics or multi-omics, critical issues like data reproducibility and interpretation, judicial validity according to Daubert standard and ethical issues of PMI research are discussed. Conclusions: Postmortem interval estimation continues to be one of the most disputed issues of forensic medicine. Conventional methods for PMI estimation still offer a solid bench for practical means. As single-omics and multi-omics research continues to progress, we will likely discover new biomarkers and innovative techniques. Efforts will focus on identifying biomarkers that can deliver reliable and predictable outcomes, thereby facilitating their general acceptance and admissibility in legal proceedings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.